Skip to main content

Table 2 Levels of candidate biomarkers (ng/ml) as detected by specific ELISA assays

From: AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease

  Cirrhosis Cirrhosis + HCC
  Mean ± S.D. median Mean ± S.D. median
AFP 5.96 ± 2.65 5.00 5934.66 ± 13025.02 92.50
PIVKAII 23.47 ± 59.69 7.83 135.17 ± 168.96 42.75
GP3 125.41 ± 281.05 29.62 161.41 ± 422.33 56.57
Follistatin 72.41 ± 76.16 50.20 87.33 ± 131.31 61.35
  1. The mean level between cirrhotic patients versus cirrhotic patients with cancer was significantly different in the cases of AFP and PIVKAII (p = 0.004 and p < 0.001 respectively, Wilcoxon). There was no significant difference between levels for GP3, CD5L or Follistatin.